- Home
- REFI vs PLYX Comparison
REFI vs PLYX Comparison
Compare REFI & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | PLYX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 271.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | PLYX |
|---|---|---|
| Price | $11.50 | $5.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 189.8K | ★ 936.9K |
| Earning Date | 05-06-2026 | 05-22-2026 |
| Dividend Yield | ★ 16.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $15.98 | N/A |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | $6.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.74 | $2.20 |
| 52 Week High | $15.20 | $9.18 |
Technical Indicators
Market Signals| Indicator | REFI | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 48.10 |
| Support Level | $10.74 | $4.95 |
| Resistance Level | $12.59 | $7.43 |
| Average True Range (ATR) | 0.29 | 1.21 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 41.99 | 15.84 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.